ArticleBMC infectious diseases2025
Pristinamycin-antibiotic combinations against methicillin-resistant Staphylococcus aureus recovered from skin infections.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Pyrrolidine in Antibacterial Drug Discovery: Clinically Approved Antibiotics, Novel Derivatives, and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMacrolide-resistant and methicillin-resistant Staphylococcus aureus, particularly those exhibiting pristinamycin resistance, impose significant medical health consequences with limited therapeutic options. This study is designed to determine their prevalence in a major tertiary care hospital in Egypt, antimicrobial susceptibility and evaluate various pristinamycin (PST)-antibiotic combinations.
methodsStandard procedures were employed for isolation, identification, antimicrobial susceptibility, and molecular analysis of key macrolide- and methicillin-resistant genes. Phenotypic relatedness and antibiotic combinations of pristinamycin with other antimicrobial agents were done using the heatmap analysis and checkerboard assay.
resultsOut of 154 positive cultures of S. aureus were collected from different types of skin infections. The lowest resistance was shown for linezolid (5.2%), followed by vancomycin (9.1%), teicoplanin (9.1%), chloramphenicol (12.3%), and doxycycline (14.9%). The MDR isolates (43%, n = 67) showed diverse phenotypic relatedness. They showed multiple antibiotic resistance (MAR) index range from 0.31-1.0, exhibiting 100% non-susceptibility to cefoxitin (MRSA), erythromycin, and clarithromycin known as macrolide resistant S. aureus (McRSA), followed by 80%, 74.6%, and 46.2% for clindamycin, azithromycin, and PST, respectively. All the MDR isolates gave positive nuc, mecA and confirmed MRSA. The ermC, ermA, and msrA, genes were detected in 49.25%, 26.8%, and 23.8% of the MDR isolates, respectively. The PST-doxycycline and PST-levofloxacin combinations were mostly synergistic in 82.13% and 70.14%, while PST-linezolid showed mostly additive effects in 67% of the MDR S. aureus isolates.
conclusionThis study highlights the high prevalence of MRSA isolates recovered from various skin infections. Linezolid, vancomycin, teicoplanin, pristinamycin, chloramphenicol, and doxycycline remain effective therapeutic options. Macrolide and methicillin resistance are increasingly developing among S. aureus clinical isolates. The pristinamycin combination with doxycycline or levofloxacin was mostly synergistic and recommended for clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.